Hyper‐progressive disease after immune checkpoint inhibitor in SMARCA4‐deficient small‐cell lung carcinoma
Abstract SMARCA4 (switch/sucrose non‐fermentable‐related, matrix‐associated, actin‐dependent regulator of chromatin, subfamily A, member 4)‐deficient thoracic tumours have shown poor prognosis in clinical settings. Although the optimal treatment for SMARCA4‐deficient thoracic tumours remains unclear...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2020-11-01
|
| Series: | Respirology Case Reports |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/rcr2.667 |